Success Metrics

Clinical Success Rate

100.0%

Based on 7 completed trials

Completion Rate

100%(7/7)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

Phase 2Efficacy & side effects

1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Terminated(1)

Detailed Status

Completed7

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

completed788%

withdrawn113%

Recent Activity

0 active trials

Showing 5 of 8

completed

REAl LIfe" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients

NCT07473986

completed

Clinical Trials (8)

Showing 8 of 8 trials

NCT07473986

REAl LIfe" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients

Completed

NCT05712096

eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services

Completed

NCT05667116

eVusheld Assessment reaL wORld Effectiveness at UPMC

Completed

NCT05569408

eVusheld Assessment reaL wORld Effectiveness in DoD Health System

Completed

NCT05663957

eVusheld Assessment reaL wORld Effectiveness in the VA Health System

Completed

NCT05461378

PREP (Pre-Exposure Prophylaxis) of COVID-19

Completed

NCT06156982

An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan

Completed

NCT05465876Phase 2

Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8